NCT05830097: An ongoing trial by Coherent Biopharma (Hefei) Co., Ltd.
This trial is ongoing. It must report results 2 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05830097 |
|---|---|
| Title | An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 14, 2023 |
| Completion date | June 30, 2025 |
| Required reporting date | June 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |